glp-1/gip/glucagon triple agonist name LY3437943, a novel glucagon, GIP, and GLP-1 receptor for glycemic control and weight loss: From discovery to clinical proof of concept Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic
Description
Observational studies reporting vitamin D and micronutrient insufficiencies during prolonged GLP-1RA use [94, 95, 101] suggest that nutritional monitoring may be warranted, although the magnitude and causal pathways remain to be clarified
doi: 10.2337/dc19-S004
Burcelin R, Gourdy P, Dalle S
Millions of Americans have shed pounds with help from drugs like Wegovy and Zepbound
If you or a loved one has suffered from severe side effects after using Ozempic or other GLP-1 drugs, you may be eligible to join the Ozempic Lawsuit
